Vigabatrin

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585200

CAS#: 68506-86-5

Description: Vigabatrin is an anti-epileptic compound that inhibits the breakdown of γ-aminobutyric acid (GABA).


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-04-09. Prices are subject to change without notice.

Vigabatrin is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 585200
Name: Vigabatrin
CAS#: 68506-86-5
Chemical Formula: C6H11NO2
Exact Mass: 129.079
Molecular Weight: 129.159
Elemental Analysis: C, 55.80; H, 8.58; N, 10.84; O, 24.77


Synonym: Vigabatrin; Sabril; CPP 109; CPP109; CPP-109

IUPAC/Chemical Name: 5-Hexenoic acid, 4-amino-

InChi Key: PJDFLNIOAUIZSL-UHFFFAOYSA-N

InChi Code: InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

SMILES Code: C=CC(N)CCC(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Chiron C. Stiripentol and vigabatrin current roles in the treatment of epilepsy. Expert Opin Pharmacother. 2016 Jun;17(8):1091-101. doi: 10.1517/14656566.2016.1161026. Epub 2016 Mar 17. Review. PubMed PMID: 26933940.

2: O'Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; participating investigators. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017 Jan;16(1):33-42. doi: 10.1016/S1474-4422(16)30294-0. Epub 2016 Nov 10. PubMed PMID: 27838190.

3: Ko A, Youn SE, Chung HJ, Kim SH, Lee JS, Kim HD, Kang HC. Vigabatrin and high-dose prednisolone therapy for patients with West syndrome. Epilepsy Res. 2018 Sep;145:127-133. doi: 10.1016/j.eplepsyres.2018.06.013. Epub 2018 Jun 23. PubMed PMID: 29966811.

4: Tolbert D, Reid S, Harris S, Bekersky I. Vigabatrin Lacks Proarrhythmic Potential: Results from a Thorough QT/QTc Study in Healthy Volunteers. Clin Ther. 2017 Aug;39(8):1639-1648. doi: 10.1016/j.clinthera.2017.06.006. Epub 2017 Jun 28. PubMed PMID: 28668627.

5: Jackson MC, Jafarpour S, Klehm J, Thome-Souza S, Coughlin F, Kapur K, Loddenkemper T. Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy. Epilepsia. 2017 Sep;58(9):1575-1585. doi: 10.1111/epi.13836. Epub 2017 Jul 10. PubMed PMID: 28691157.

6: Hussain SA, Tsao J, Li M, Schwarz MD, Zhou R, Wu JY, Salamon N, Sankar R. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. Epilepsia. 2017 Apr;58(4):674-682. doi: 10.1111/epi.13712. Epub 2017 Feb 23. PubMed PMID: 28230253.

7: Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP; United Kingdom Infantile Spasms Study. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005 Nov;4(11):712-7. PubMed PMID: 16239177.

8: Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447):1773-8. PubMed PMID: 15541450.

9: French JA. Vigabatrin. Epilepsia. 1999;40 Suppl 5:S11-6. Review. PubMed PMID: 10530689.

10: Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007302. doi: 10.1002/14651858.CD007302.pub2. Review. PubMed PMID: 23440814.

11: Wheless JW, Ramsay RE, Collins SD. Vigabatrin. Neurotherapeutics. 2007 Jan;4(1):163-72. Review. PubMed PMID: 17199033.

12: Xiao Y, Gan L, Wang J, Luo M, Luo H. Vigabatrin versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev. 2015 Nov 18;(11):CD008781. doi: 10.1002/14651858.CD008781.pub3. Review. PubMed PMID: 26580100.

13: Knupp KG. Hormonal therapy with vigabatrin is superior to hormonal therapy alone in infantile spasms. J Pediatr. 2017 May;184:235-238. doi: 10.1016/j.jpeds.2017.02.051. PubMed PMID: 28434569.

14: O'Callaghan FJK, Edwards SW, Alber FD, Cortina Borja M, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay MT, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; International Collaborative Infantile Spasms Study (ICISS) investigators. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2018 Oct;2(10):715-725. doi: 10.1016/S2352-4642(18)30244-X. Epub 2018 Aug 29. PubMed PMID: 30236380.

15: Ohtsuka Y. Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: Primary short-term study and extension study. Epilepsy Behav. 2018 Jan;78:134-141. doi: 10.1016/j.yebeh.2017.09.010. Epub 2017 Dec 22. PubMed PMID: 29190579.

16: D'Alonzo R, Rigante D, Mencaroni E, Esposito S. West Syndrome: A Review and Guide for Paediatricians. Clin Drug Investig. 2018 Feb;38(2):113-124. doi: 10.1007/s40261-017-0595-z. Review. PubMed PMID: 29086890.

17: Nøhr MK, Juul RV, Thale ZI, Holm R, Kreilgaard M, Nielsen CU. Is oral absorption of vigabatrin carrier-mediated? Eur J Pharm Sci. 2015 Mar 10;69:10-8. doi: 10.1016/j.ejps.2014.12.018. Epub 2015 Jan 3. PubMed PMID: 25562534.

18: Spelbrink EM, Mabud TS, Reimer R, Porter BE. Plasma taurine levels are not affected by vigabatrin in pediatric patients. Epilepsia. 2016 Aug;57(8):e168-72. doi: 10.1111/epi.13447. Epub 2016 Jun 26. PubMed PMID: 27344989.

19: Zhao J, Shin Y, Jin Y, Jeong KM, Lee J. Determination of enantiomeric vigabatrin by derivatization with diacetyl-l-tartaric anhydride followed by ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:199-207. doi: 10.1016/j.jchromb.2016.11.016. Epub 2016 Nov 10. PubMed PMID: 27866846.

20: Hussain K, Walsh TJ, Chazen JL. Brain MRI findings with vigabatrin therapy: case report and literature review. Clin Imaging. 2016 Jan-Feb;40(1):180-2. doi: 10.1016/j.clinimag.2015.07.016. Epub 2015 Jul 17. Review. PubMed PMID: 26526789.